Clinical Medical Research Award
For his demonstration of the effectiveness of large daily dosages of L-DOPA in the treatment of Parkinson's disease.
Parkinson's disease, often called "shaking palsy," is a disease that, in this country alone, claims 1.5 million victims.
The remarkable contribution of Dr. Cotzias and his colleagues is the dramatic demonstration that large, daily dosages of L-DOPA can reverse most of the crippling effects of Parkinsonism. In an editorial in the New England Journal of Medicine, their work is called "the most important contribution to medical therapy of neurological disease in the past 50 years."
The significance and implications of this work are enormous. The basic research that led to Dr. Cotzias's method of treatment with Parkinsonism with L-DOPA has opened the way to the treatment of other neurological diseases and has created the need for new neurochemical concepts.
Dr. Cotzias' contributions are the product of imaginative hypotheses, perceptive analytical thinking, laboratory experimentation, and careful clinical investigation. They have clearly projected the future role of neurochemistry in the treatment of neurological diseases.
To Dr. Cotzias, a brilliant scientist deeply dedicated to the conviction that through basic medical research and its application to clinical research, the human suffering of crippling disease can be eliminated, this 1969 Albert Lasker Clinical Medical Research Award is given.